Filing Flows › Bioventus (BVS) › Guidance history
Bioventus (BVS) guidance history: what it guided and what it reported
Bioventus gave guidance in 2 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $590M–$595M (Nov 2, 2026) | — | to be reported | — |
Adjusted EPS
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $0.75–$0.79 (May 6, 2026) → reaffirmed $0.75–$0.79 (Nov 2, 2026) | — | to be reported | — |
The latest quarter
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Bioventus beat its guidance?
Bioventus gave guidance in 2 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Bioventus raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.